Proteomic Analysis Identifies Dysregulated Proteins in Albuminuria: A South African Pilot Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Ethics Statement
2.2. The Study Population
2.3. Clinical Laboratory Tests
2.4. Urine Protein Extraction
2.5. Retrospective Power Analysis
2.6. Data Analysis and Pathway Analysis
3. Results
3.1. Clinical and Demographic Characteristics of Patients
3.2. Performance of Study-Specific System Suitability-Quality Control
3.3. Differentially Abundant Proteins between Cases and Controls
3.4. Potential Markers for Albuminuria and Normoalbuminuria Classification
3.5. Functional Enrichment Analysis of Differentially Abundant Proteins
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond. Engl. 2020, 395, 709–733. [Google Scholar] [CrossRef] [PubMed]
- Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; O’Callaghan, C.A.; Lasserson, D.S.; Hobbs, F.R. Global prevalence of chronic kidney disease—A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11, e0158765. [Google Scholar] [CrossRef] [PubMed]
- Wang, H.; Naghavi, M.; Allen, C.; Barber, R.M.; Bhutta, Z.A.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; Coates, M.M.; et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016, 388, 1459–1544. [Google Scholar] [CrossRef]
- Stevens, P.E.; Ahmed, S.B.; Carrero, J.J.; Foster, B.; Francis, A.; Hall, R.K.; Herrington, W.G.; Hill, G.; Inker, L.A.; Lamb, E.J.; et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024, 105, S117–S314. [Google Scholar]
- Kidney Diseases Improving Global Outcomes (KDIGO) CKD Work Group. Clinical Practice Guidelines for Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 2013, 3, 1–150. [Google Scholar]
- Levey, A.S.; De Jong, P.E.; Coresh, J.; El Nahas, M.; Astor, B.C.; Matsushita, K.; Gansevoort, R.T.; Kasiske, B.L.; Eckardt, K.U. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int. 2011, 80, 17–28. [Google Scholar] [CrossRef] [PubMed]
- Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet 2010, 375, 2073–2081. [Google Scholar] [CrossRef] [PubMed]
- Lambers Heerspink, H.J.; Gansevoort, R.T. Albuminuria is an appropriate therapeutic target in patients with CKD: The pro view. Clin. J. Am. Soc. Nephrol. Cjasn. 2015, 10, 1079–1088. [Google Scholar] [CrossRef]
- Abbate, M.; Zoja, C.; Remuzzi, G. How Does Proteinuria Cause Progress. Ren. Damage? J. Am. Soc. Nephrol. 2006, 17, 2974–2984. [Google Scholar] [CrossRef]
- Berhane, A.M.; Weil, E.J.; Knowler, W.C.; Nelson, R.G.; Hanson, R.L. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin. J. Am. Soc. Nephrol. 2011, 6, 2444–2451. [Google Scholar] [CrossRef]
- Leong, A.; Ekinci, E.I.; Nguyen, C.; Milne, M.; Hachem, M.; Dobson, M.; MacIsaac, R.J.; Jerums, J. Long-term intra-individual variability of albuminuria in type 2 diabetes mellitus: Implications for categorization of albumin excretion rate. BMC Nephrol. 2017, 18, 355. [Google Scholar] [CrossRef] [PubMed]
- Currie, G.E.; von Scholten, B.J.; Mary, S.; Flores Guerrero, J.L.; Lindhardt, M.; Reinhard, H.; Mischak, H.; Rossing, P.; Delles, C. Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria. Cardiovasc. Diabetol. 2018, 17, 50. [Google Scholar] [CrossRef] [PubMed]
- Rodríguez-Ortiz, M.E.; Pontillo, C.; Rodríguez, M.; Zürbig, P.; Mischak, H.; Ortiz, A. Novel urinary biomarkers for improved prediction of progressive eGFR loss in early chronic kidney disease stages and in high risk individuals without chronic kidney disease. Sci. Rep. 2018, 8, 15940. [Google Scholar] [CrossRef] [PubMed]
- Ahn, H.S.; Kim, J.H.; Jeong, H.; Yu, J.; Yeom, J.; Song, S.H.; Kim, S.S.; Kim, I.J.; Kim, K. Differential urinary proteome analysis for predicting prognosis in type 2 diabetes patients with and without renal dysfunction. Int. J. Mol. Sci. 2020, 21, 4236. [Google Scholar] [CrossRef] [PubMed]
- Zürbig, P.; Jerums, G.; Hovind, P.; MacIsaac, R.J.; Mischak, H.; Nielsen, S.E.; Panagiotopoulos, S.; Persson, F.; Rossing, P. Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes 2012, 61, 3304–3313. [Google Scholar] [CrossRef] [PubMed]
- Dubin, R.F.; Rhee, E.P. Proteomics and metabolomics in kidney disease, including Insights into etiology, treatment, and prevention. Clin. J. Am. Soc. Nephrol. 2020, 15, 404–411. [Google Scholar] [CrossRef]
- Øvrehus, M.A.; Zürbig, P.; Vikse, B.E.; Hallan, S.I. Urinary proteomics in chronic kidney disease: Diagnosis and risk of progression beyond albuminuria. Clin. Proteom. 2015, 12, 21. [Google Scholar] [CrossRef]
- Fan, G.; Gong, T.; Lin, Y.; Wang, J.; Sun, L.; Wei, H.; Yang, X.; Liu, Z.; Li, X.; Zhao, L.; et al. Urine proteomics identifies biomarkers for diabetic kidney disease at different stages. Clin. Proteom. 2021, 18, 32. [Google Scholar] [CrossRef]
- Gajjala, P.R.; Bruck, H.; Noels, H.; Heinze, G.; Ceccarelli, F.; Kribben, A.; Saez-Rodriguez, J.; Marx, N.; Zidek, W.; Jankowski, J.; et al. Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach. J. Mol. Med. 2019, 97, 1451–1463. [Google Scholar] [CrossRef]
- De Beer, D.; Mels, C.M.; Schutte, A.E.; Delles, C.; Mary, S.; Mullen, W.; Latosinska, A.; Mischak, H.; Kruger, R. Identifying a urinary peptidomics profile for hypertension in young adults: The African-PREDICT study: Urinary peptidomics and hypertension. Proteomics 2023, 23, 2200444. [Google Scholar] [CrossRef]
- Govender, M.A.; Stoychev, S.H.; Brandenburg, J.T.; Ramsay, M.; Fabian, J.; Govender, I.S. Proteomic insights into the pathophysiology of hypertension-associated albuminuria: Pilot study in a South African cohort. Clin. Proteom. 2024, 21, 15. [Google Scholar] [CrossRef] [PubMed]
- Kalyesubula, R.; Fabian, J.; Nakanga, W.; Newton, R.; Ssebunnya, B.; Prynn, J.; George, J.; Wade, A.N.; Seeley, J.; Nitsch, N.; et al. How to estimate glomerular filtration rate in sub-Saharan Africa: Design and methods of the African Research into Kidney Diseases (ARK) study. BMC Nephrol. 2020, 21, 20. [Google Scholar] [CrossRef] [PubMed]
- Harris, P.A.; Taylor, R.; Thielke, R.; Payne, J.; Gonzalez, N.; Conde, J.G. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support. J. Biomed. Inform. 2009, 42, 377–381. [Google Scholar] [CrossRef] [PubMed]
- Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., Jr.; et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42, 1206–1252. [Google Scholar] [CrossRef]
- Fabian, J.; Gondwe, M.; Mayindi, N.; Chipungu, S.; Khoza, B.; Gaylard, P.; Wade, A.N.; Gómez-Olivé, F.X.; Tomlinson, L.A.; Ramsay, M.; et al. Chronic kidney disease (CKD) and associated risk in rural South Africa: A population-based cohort study. Wellcome Open Res. 2022, 7, 236. [Google Scholar] [CrossRef]
- George, J.A.; Brandenburg, J.T.; Fabian, J.; Crowther, N.J.; Agongo, G.; Alberts, M.; Ali, S.; Asiki, G.; Boua, P.R.; Gómez-Olivé, F.X.; et al. Kidney damage and associated risk factors in rural and urban sub-Saharan Africa (AWI-Gen): A cross-sectional population study. Lancet Glob. Health 2019, 7, e1632–e1643. [Google Scholar] [CrossRef]
- Reiter, L.; Rinner, O.; Picotti, P.; Hüttenhain, R.; Beck, M.; Brusniak, M.Y.; Hengartner, M.O.; Aebersold, R. mProphet: Automated data processing and statistical validation for large-scale SRM experiments. Nat. Methods 2011, 8, 430–435. [Google Scholar] [CrossRef]
- Zhang, B.; Chambers, M.C.; Tabb, D.L. Proteomic Parsimony through Bipartite Graph Analysis Improves Accuracy and Transparency. J. Proteome Res. 2007, 6, 3549–3557. [Google Scholar] [CrossRef]
- Costanzo, M.; Caterino, M.; Salvatori, I.; Manganelli, V.; Ferri, A.; Misasi, R.; Ruoppolo, M. Proteome data of neuroblastoma cells overexpressing Neuroglobin. Data Brief 2022, 41, 107843. [Google Scholar] [CrossRef]
- Shan, G. Monte Carlo cross-validation for a study with binary outcome and limited sample size. BMC Med. Inf. Decis. Mak. 2022, 22, 270. [Google Scholar] [CrossRef]
- Evangelista, J.E.; Xie, Z.; Marino, G.B.; Nguyen, N.; Clarke, D.J.B.; Ma’ayan, A. Enrichr-KG: Bridging enrichment analysis across multiple libraries. Nucleic Acids Res. 2023, 51, W168–W179. [Google Scholar] [CrossRef] [PubMed]
- Chen, E.Y.; Tan, C.M.; Kou, Y.; Duan, Q.; Wang, Z.; Meirelles, G.V.; Clark, N.R.; Ma’ayan, A. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013, 14, 128. [Google Scholar] [CrossRef] [PubMed]
- Barratt, J.; Topham, P. Urine proteomics: The present and future of measuring urinary protein components in disease. Can. Med. Assoc. J. 2007, 177, 361–368. [Google Scholar] [CrossRef] [PubMed]
- Chebotareva, N.; Vinogradov, A.; McDonnell, V.; Zakharova, N.V.; Indeykina, M.I.; Moiseev, S.; Nikolaev, E.N.; Kononikhin, A.S. Urinary protein and peptide markers in chronic kidney disease. Int. J. Mol. Sci. 2021, 22, 12123. [Google Scholar] [CrossRef]
- Kaburagi, Y.; Takahashi, E.; Kajio, H.; Yamashita, S.; Yamamoto-Honda, R.; Shiga, T.; Okumura, A.; Goto, A.; Fukazawa, Y.; Seki, N.; et al. Urinary afamin levels are associated with the progression of diabetic nephropathy. Diabetes Res. Clin. Pract. 2019, 147, 37–46. [Google Scholar] [CrossRef]
- Ning, J.; Xiang, Z.; Xiong, C.; Zhou, Q.; Wang, X.; Zou, H. Alpha1-Antitrypsin in Urinary Extracellular Vesicles: A Potential Biomarker of Diabetic Kidney Disease Prior to Microalbuminuria. Diabetes Metab. Syndr. Obes. Targets Ther. 2020, 13, 2037–2048. [Google Scholar] [CrossRef]
- Boulle, A. Antiretroviral therapy and early mortality in South Africa. Bull. World Health Organ. 2008, 86, 678–687. [Google Scholar] [CrossRef]
- Kim, P.S.; Woods, C.; Dutcher, L.; Georgoff, P.; Rosenberg, A.; Mican, J.A.M.; Kopp, J.B.; Smith, M.A.; Hadigan, C. Increased Prevalence of Albuminuria in HIV-Infected Adults with Diabetes. PLoS ONE 2011, 6, e24610. [Google Scholar] [CrossRef]
- Assaram, S.; Magula, N.P.; Mewa Kinoo, S.; Mashamba-Thompson, T.P. Renal manifestations of HIV during the antiretroviral era in South Africa: A systematic scoping review. Syst. Rev. 2017, 6, 200. [Google Scholar] [CrossRef]
- Zoccali, C.; Vanholder, R.; Massy, Z.A.; Ortiz, A.; Sarafidis, P.; Dekker, F.W.; Fliser, D.; Fouque, D.; Heine, G.H.; Jager, K.J.; et al. The systemic nature of CKD. Nat. Rev. Nephrol. 2017, 13, 344–358. [Google Scholar] [CrossRef]
- Ikezumi, Y.; Hurst, L.; Atkins, R.C.; Nikolic-Paterson, D.J. Macrophage-mediated renal injury is dependent on signaling via the JNK pathway. J. Am. Soc. Nephrol. 2004, 15, 1775–1784. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.X.; Wang, S.; Huang, X.; Min, W.P.; Sun, H.; Liu, W.; Garcia, B.; Jevnikar, A.M. NK cells induce apoptosis in tubular epithelial cells and contribute to renal ischemia-reperfusion injury. J. Immunol. 2008, 181, 7489–7498. [Google Scholar] [CrossRef]
- Wang, S.; Chi, K.; Wu, D.; Hong, Q. Insulin-Like Growth Factor Binding Proteins in Kidney Disease. Front Pharmacol. 2021, 12, 807119. [Google Scholar] [CrossRef] [PubMed]
- Worthmann, K.; Peters, I.; Kümpers, P.; Saleem, M.; Becker, J.U.; Agustian, P.A.; Achenbach, J.; Haller, H.; Schiffer, M. Urinary excretion of IGFBP-1 and -3 correlates with disease activity and differentiates focal segmental glomerulosclerosis and minimal change disease. Growth Factors 2010, 28, 129–138. [Google Scholar] [CrossRef]
- Ravassa, S.; Beaumont, J.; Cediel, G.; Lupón, J.; López, B.; Querejeta, R.; Díez, J.; Bayés-Genís, A.; González, A. Cardiorenal interaction and heart failure outcomes. A role for insulin-like growth factor binding protein 2? Rev. Esp. Cardiol. Engl. Ed. 2020, 73, 835–843. [Google Scholar] [CrossRef]
- Gokulakrishnan, K.; Velmurugan, K.; Ganesan, S.; Mohan, V. Circulating levels of insulin-like growth factor binding protein–1 in relation to insulin resistance, type 2 diabetes mellitus, and metabolic syndrome (Chennai Urban Rural Epidemiology Study 118). Metabolism 2012, 61, 43–46. [Google Scholar] [CrossRef]
- Bach, L.A.; Hale, L.J. Insulin-like Growth Factors and Kidney Disease. Am. J. Kidney Dis. 2015, 65, 327–336. [Google Scholar] [CrossRef]
- Gao, L.; Zhong, X.; Jin, J.; Li, J.; Meng, X. Potential targeted therapy and diagnosis based on novel insight into growth factors, receptors, and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression. Signal Transduct. Target. Ther. 2020, 5, 9. [Google Scholar] [CrossRef] [PubMed]
- Cai, D.; Chen, Q.; Mao, L.; Xiao, T.; Wang, Y.; Gu, Q.; Wang, Q.; Ji, Y.; Sun, L. Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients. Eur. J. Clin. Pharmacol. 2024, 80, 613–620. [Google Scholar] [CrossRef]
- Heerspink, H.J.; Stefánsson, B.V.; Correa-Rotter, R.; Chertow, G.M.; Greene, T.; Hou, F.F.; Mann, J.F.; McMurray, J.J.; Lindberg, M.; Rossing, P.; et al. Dapagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med. 2020, 383, 1436–1446. [Google Scholar] [CrossRef]
- Gremmel, T.; Müller, M.; Steiner, S.; Seidinger, D.; Koppensteiner, R.; Kopp, C.W.; Panzer, S. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol. Dial. Transpl. 2013, 28, 2116–2122. [Google Scholar] [CrossRef]
- Huang, H.S.; Chang, H.H. Platelets in inflammation and immune modulations: Functions beyond hemostasis. Arch. Immunol. Ther. Exp. 2012, 60, 443–451. [Google Scholar] [CrossRef] [PubMed]
- Jain, N.; Corken, A.L.; Kumar, A.; Davis, C.L.; Ware, J.; Arthur, J.M. Role of platelets in chronic kidney disease. J. Am. Soc. Nephrol. JASN 2021, 32, 1551–1558. [Google Scholar] [CrossRef]
- Podkowińska, A.; Formanowicz, D. Chronic kidney disease as oxidative stress- and inflammatory-mediated cardiovascular disease. Antioxidants 2020, 9, 752. [Google Scholar] [CrossRef]
- Annuk, M.; Zilmer, M.; Lind, L.; Linde, T.; Fellström, B. Oxidative stress and endothelial function in chronic renal failure. J. Am. Soc. Nephrol. 2001, 12, 2747–2752. [Google Scholar] [CrossRef]
- Ounousi, E.; Papavasiliou, E.; Makedou, A.; Ioannou, K.; Katopodis, K.P.; Tselepis, A.; Siamopoulos, K.C.; Tsakiris, D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am. J. Kidney Dis. 2006, 48, 752–760. [Google Scholar]
- Kim, K.P.; Williams, C.E.; Lemmon, C.A. Cell–matrix interactions in renal fibrosis. Kidney Dial. 2022, 2, 607–624. [Google Scholar] [CrossRef]
- Pontillo, C.; Jacobs, L.; Staessen, J.A.; Schanstra, J.P.; Rossing, P.; Heerspink, H.J.; Siwy, J.; Mullen, W.; Vlahou, A.; Mischak, H.; et al. A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrol. Dial. Transplant. 2016, 32, 1510–1516. [Google Scholar]
- Pruijm, M.; Ponte, B.; Ackermann, D.; Paccaud, F.; Guessous, I.; Ehret, G.; Pechere-Bertschi, A.; Vogt, B.; Mohaupt, M.G.; Martin, P.Y.; et al. Associations of urinary uromodulin with clinical characteristics and markers of tubular function in the general Population. Clin. J. Am. Soc. Nephrol. 2016, 11, 70–80. [Google Scholar] [CrossRef] [PubMed]
- Rasmussen, D.G.K.; Boesby, L.; Nielsen, S.H.; Tepel, M.; Birot, S.; Karsdal, M.A.; Kamper, A.L.; Genovese, F. Collagen turnover profiles in chronic kidney disease. Sci. Rep. 2019, 9, 16062. [Google Scholar] [CrossRef]
- Genovese, F.; Rasmussen, D.G.K.; Karsdal, M.A.; Jesky, M.; Ferro, C.; Fenton, A.; Cockwell, P. Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients. Clin. Kidney J. 2021, 14, 593–601. [Google Scholar] [CrossRef] [PubMed]
- Bülow, R.D.; Boor, P. Extracellular Matrix in Kidney Fibrosis: More Than Just a Scaffold. J. Histochem. Cytochem. 2019, 67, 643–661. [Google Scholar] [CrossRef] [PubMed]
- Mahendran, K.B.; Bhaskar, M.V.; Santha, K.; Inmozhi, R.; Perumal, K.K. Plasma and Urinary Type IV Collagen Levels for Early Detection of Nephropathy in Type 2 Diabetes Mellitus Patients. Int. J. Health Sci. 2016, 10, 492–498. [Google Scholar]
- Furumatsu, Y.; Nagasawa, Y.; Shoji, T.; Yamamoto, R.; Iio, K.; Matsui, I.; Takabatake, Y.; Kaimori, J.Y.; Iwatani, H.; Kaneko, T.; et al. Urinary Type IV Collagen in Nondiabetic Kidney Disease. Nephron. Clin. Pract. 2010, 117, c160–c166. [Google Scholar] [CrossRef]
- Catania, J.M.; Chen, G.; Parrish, A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am. J. Physiol. Ren. Physiol. 2007, 292, F905–F911. [Google Scholar] [CrossRef] [PubMed]
- Good, D.M.; Zürbig, P.; Argiles, A.; Bauer, H.W.; Behrens, G.; Coon, J.J.; Dakna, M.; Decramer, S.; Delles, C.; Dominiczak, A.F.; et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteom. MCP 2010, 9, 2424–2437. [Google Scholar] [CrossRef]
- Prikryl, P.; Vojtova, L.; Maixnerova, D.; Vokurka, M.; Neprasova, M.; Zima, T.; Tesar, V. Proteomic approach for identification of IgA nephropathy-related biomarkers in urine. Physiol. Res. 2017, 66, 621–632. [Google Scholar] [CrossRef]
- Devuyst, O.; Bochud, M. Uromodulin, kidney function, cardiovascular disease, and mortality. Kidney Int. 2015, 88, 944–946. [Google Scholar] [CrossRef]
- Shao, C.; Yan, W.; Gao, Y. Application of urinary proteomics in biomarker discovery. Sci. China Life Sci. 2011, 54, 409–417. [Google Scholar] [CrossRef]
- Puthumana, J.; Thiessen-Philbrook, H.; Xu, L.; Coca, S.G.; Garg, A.X.; Himmelfarb, J.; Bhatraju, P.K.; Ikizler, T.A.; Siew, E.D.; Ware, L.B.; et al. Biomarkers of inflammation and repair in kidney disease progression. J. Clin. Investig. 2021, 131, e139927. [Google Scholar] [CrossRef]
- Wen, Y.; Xu, L.; Melchinger, I.; Thiessen-Philbrook, H.; Moledina, D.G.; Coca, S.G.; Hsu, C.Y.; Go, A.S.; Liu, K.D.; Siew, E.D.; et al. Longitudinal biomarkers and kidney disease progression after acute kidney injury. JCI Insight 2023, 8, e167731. [Google Scholar] [CrossRef] [PubMed]
- Perez-Riverol, Y.; Bai, J.; Bandla, C.; García-Seisdedos, D.; Hewapathirana, S.; Kamatchinathan, S.; Kundu, D.J.; Prakash, A.; Frericks-Zipper, A.; Eisenacher, M.; et al. The PRIDE database resources in 2022: A hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022, 7, D543–D552. [Google Scholar] [CrossRef] [PubMed]
Variable | Total | Cases (n = 56) | Controls (n = 52) | p-Value |
---|---|---|---|---|
Age, years | 42 (30–54) | 42 (30–55) | 42 (31–53) | 0.987 |
Women | 61/108 (57) | 32/56 (57) | 29/52 (56) | 0.886 |
BMI, kg/m2 | 25 (22–29) | 25 (21–28) | 25 (23–33) | 0.428 |
Serum creatinine, µmol/L | 63 (53–74) | 63 (53–76) | 63 (52–71) | 0.550 |
eGFR, mL/min/1.73 m2 | 113 (95–124) | 111(93–124) | 114 (99–124) | 0.707 |
uACR, mg/mmol | 3.9 (0.6–8.4) | 7.9 (5.5–18.5) | 0.6 (0.30–1.1) | <0.001 |
HPT status | 12/108 (11) | 8/45 (18) | 4/46 (9) | 0.439 |
Diabetes status | 3/108 (2.7) | 3/26 (12) | 0/28 (0.0) | 0.064 |
HIV status | 35/108 (32) | 22/56 (39) | 13/52 (25) | 0.033 |
Smoking | 17/108 (16) | 8/56 (14) | 9/52 (17) | 0.667 |
Glucose, mmol/L | 6.3 (5.6–7.7) | 6.3 (5.7–7.7) | 6.4 (5.6–7.5) | 0.848 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Khoza, S.; George, J.A.; Naicker, P.; Stoychev, S.H.; Fabian, J.; Govender, I.S. Proteomic Analysis Identifies Dysregulated Proteins in Albuminuria: A South African Pilot Study. Biology 2024, 13, 680. https://doi.org/10.3390/biology13090680
Khoza S, George JA, Naicker P, Stoychev SH, Fabian J, Govender IS. Proteomic Analysis Identifies Dysregulated Proteins in Albuminuria: A South African Pilot Study. Biology. 2024; 13(9):680. https://doi.org/10.3390/biology13090680
Chicago/Turabian StyleKhoza, Siyabonga, Jaya A. George, Previn Naicker, Stoyan H. Stoychev, June Fabian, and Ireshyn S. Govender. 2024. "Proteomic Analysis Identifies Dysregulated Proteins in Albuminuria: A South African Pilot Study" Biology 13, no. 9: 680. https://doi.org/10.3390/biology13090680